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Background/Objectives: Although endovascular abdominal aortic aneurysm (AAA) repair (ENDO) has decreased opera-
tive morbidity risks compared with open AAA repair (OPEN), risks of rupture and reintervention are higher after ENDO.
We used decision analysis to examine the effect of these competing risks on quality-adjusted life expectancy (QALE) after
ENDO and OPEN.
Methods: We used a Markov decision-analysis model to simulate hypothetic cohorts of patients undergoing ENDO or
OPEN. Patients moved through a multistate transition model according to probabilities derived from the literature, the
EUROSTAR database (for ENDO) and Medicare claims data (for OPEN). Our primary outcome measure was QALE
after surgery. We used sensitivity analysis to determine which factors most influenced this outcome.
Results: In the base-case analysis of 70-year-old men, life expectancy after ENDO was 7.09 quality-adjusted life years
compared with 7.03 quality-adjusted life years for OPEN, a difference of 3 weeks. Sensitivity analysis showed that at less
than age 64 years, OPEN results in greater QALE. However, the difference in QALE was small (<3 months) across the
entire range of ages studied (60 to 85 years). The optimal strategy was sensitive to changes in ENDO and OPEN operative
mortality rate, rupture rate after ENDO, late conversion to OPEN rate, ENDO revision rate, and OPEN reoperation rate.
However, the difference between OPEN and ENDO strategies was small across the plausible range of most of these
variables.
Conclusion: For most patients who are candidates for AAA repair, ENDO and OPEN result in similar QALE. Decision
analysis suggests that OPEN may be preferred for younger patients with low operative risk and ENDO may be preferred
for older patients with higher operative risk. However, given the similarity in overall outcome, patient preference should
be weighed heavily in decision making. (J Vasc Surg 2002;36:1112-20.)
Endovascular repair (ENDO) of abdominal aortic an-
eurysms (AAAs) has rapidly gained popularity since its
introduction by Parodi, Palmaz, and Barone1 in 1991.
ENDO has been shown to decrease perioperative morbid-
ity relative to standard open repair (OPEN).2 ENDO has
also been shown to decrease intensive care unit stay and
total hospital length of stay,2,3 with increased quality of life
in the perioperative period and a more rapid total recovery
time.4
In the first comparisons of ENDO with OPEN with
decision-analysis modeling, Finlayson et al5 showed that
ENDO should not change the threshold diameter for AAA
repair compared with OPEN for most patients, and Patel et
al6 determined that ENDO would provide improved sur-
vival relative to OPEN and that ENDO was cost effective.
However, these models used data from the early experience
in selected centers involved in the US multicentered trials.
Since that time, ENDO has been introduced broadly in the
United States with Food and Drug Administration ap-
proval of the Ancure (Guidant, Menlo Park, Calif) and
AneuRx (Medtronic AVE, Santa Rosa, Calif) grafts and in
other countries where a wide variety of grafts are available.
More recent experience has shown that AAA rupture
can occur after ENDO repair.7,8 In a recent publication
from the EUROSTAR database, rupture was noted to
occur at a rate of 1% per year.9 In addition, patients who
undergo ENDO need careful long-term follow-up to de-
tect and treat complications, such as graft migration, mate-
rial fatigue, endoleak with AAA sac pressurization and
enlargement, graft kinking, and thrombosis.9-11 All of
these potential problems may necessitate reintervention at a
rate that appears higher than OPEN. Conversion to OPEN
is occasionally necessary and is associated with high mortal-
ity.9,11 This has prompted some investigators to express
concern about the durability of endografts, the rupture
rate, and the need for secondary procedures, including
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conversion to OPEN. Some have even expressed the opin-
ion that ENDO is a “failed experiment.”12
The EUROSTAR database was begun in 1996 as a
voluntary, broad-based, multicenter evaluation of ENDO
outcomes, as it is broadly applied across the continent of
Europe. We designed this study to evaluate quality-ad-
justed life expectancy (QALE) for patients with AAA who
undergo either ENDO or OPEN with contemporary en-
dovascular data from the EUROSTAR database.
METHODS
Decision model
We used a Markov decision-analysis model to deter-
mine the outcomes of hypothetic cohorts of 70-year-old
men with AAA undergoing either OPEN or ENDO repair.
Hypothetic patients with AAAs suitable for repair with
either strategy transitioned between defined health states
according to probabilities derived from the literature. Pa-
tients moved through health states in 1-month cycles. All
underwent immediate surgery and were therefore exposed
to the risk of operative mortality and morbidity during the
first cycle. In addition, patients for ENDO were exposed to
the risk of early conversion to open surgery. All patients
were subsequently exposed to age-specific and disease-
specific risks of death. Patients for ENDO were exposed to
risks of revision, late conversion to OPEN, and rupture.
Patients for OPEN were exposed to the risk of reoperation
for subsequent complications of OPEN.
Patients in both groups accumulated quality-adjusted
life years (QALYs) with each cycle of the model. The model
was continued until all patients were dead and the QALE
was calculated for the two strategies. The model was devel-
oped and analyzed with the software program DATA PRO
(Decision Analysis by TreeAge, TreeAge Software, Inc,
Williamstown, Mass).
OPEN data sources
Operative mortality. The operative mortality for
OPEN, as in our previous model,5 was taken from 1995
Medicare claims for elective repair of nonruptured AAA
(n  24,386). The overall mortality rate in this group was
5.2%. This is similar to the operative mortality rate seen in
other large series: the UK Small Aneurysm Trial (5.8%),13
the US national hospital discharge survey (5.6%),14 and
Canada (5.6%).15 The operative mortality rate in the Medi-
care database varied widely by age from 3% for ages 65 to 69
years to 10% for those age 80 years and over. We therefore
used age stratified operative mortality rates for these data in
our model (Table I).
Morbidity. The major permanent morbidity after
OPEN was on the basis of a report by Johnston,16 in which
the risk of stroke was 0.5% and of renal failure 0.6%. We
assumed a permanent major morbidity rate of 1.5%.
Reoperation. Reoperation is occasionally necessary
after OPEN. For this model, we estimated an annual rate of
1% with an associated operative mortality rate of 25% on the
basis of data from the largest population-based study with
long-term follow-up from the Mayo clinic.17 In this report,
307 patients underwent AAA repair with a mean follow-up
period of 5.8 years. Of 20 patients who underwent reop-
eration (6.5%) for graft thrombosis, infection, graft-enteric
fistula, hemorrhage, or pseudoaneurysm, five (25%) died at
reoperation.
ENDO data sources
EUROSTAR. Whenever possible, probabilities in the
model for patients undergoing ENDO were derived from
the EUROSTAR database. This database represents the
largest (and only) broad-based, multicenter report of out-
comes after ENDO. Early experience in EUROSTAR con-
sisted of almost all commercial grafts that either underwent
subsequent redesign or have since been withdrawn from
the market. To capture the experience with relatively mod-
ern grafts, and yet obtain reasonable follow-up, we pro-
spectively chose to evaluate all patients entered into
EUROSTAR since January 1, 1997. This included 3222
patients who received a variety of endografts (AneuRx,
812; Ancure, 122; Excluder [WL Gore, Flagstaff, Ariz],
234; Talent [Medtronic AVE, Santa Rosa, Calif], 577;
Vanguard [Boston Scientific, Watertown, Mass], 848; Ze-
nith [Cook, Inc, Bloomington, Ind], 525; and other, 104
[including five homemade endografts]) with a mean fol-
low-up period of 13.7 months (range, 0 to 60 months).
Operative mortality. The overall operative mortality
rate in this group of EUROSTAR patients was 2.0%. As
with OPEN, the operative mortality rate of ENDO was age
dependent, ranging from 1% for patients age 60 to 64 years
to 5% for those age 80 years and more. We therefore used
age-stratified operative mortality in our model (Table I).
Morbidity. The major morbidity after ENDO varies
widely in published series.2,18,19 We assumed a risk of 1%
for permanent major morbidity after ENDO, exclusive of
morbidity associated with early conversion to OPEN.
Reoperation. Early conversion to OPEN occurred in
1.5% of patients in the recent EUROSTAR experience.
Secondary interventions occurred at a rate of 10% per year.
This included a 1% per year conversion to OPEN and a 9%
per year revision rate (8%/y transfemoral and 1%/y ex-
traanatomic). We used these rates in our model.
Rupture. An earlier report from EUROSTAR showed
a 1% per year risk of rupture after ENDO.9 However, in this
more recent analysis prepared for this model, this risk was
0.46% per year with an associated mortality rate of 56%.
Life expectancy and quality of life
QALE was calculated by reducing life expectancy to
reflect the diminished value of time spent in a morbid
condition. This quality adjustment factor typically ranges
from 0 for death to 1.0 for full health. Therefore, for
patients with major morbidity, each year of life with that
morbidity was valued as a fraction of 1 year. In our model,
we used a quality adjustment factor of 0.65 for patients with
long-term major morbidity reflective of chronic renal fail-
ure and stroke.20,21 The model was designed to determine
the average QALE for each strategy of AAA repair, namely
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OPEN and ENDO. To adjust for the diminished quality of
life in the perioperative period, we subtracted 1 month of
life for those undergoing OPEN and 1 week of life for those
undergoing ENDO. In addition to tabulated age-adjusted,
gender-adjusted, and race-adjusted mortality, all patients in
the model were subjected to excess mortality associated
with AAA disease, and those with morbidity were subjected
to an additional excess mortality (Table I). Discounting is
often used to reflect patient preferences for more immedi-
ate life years over future life years. In our model, we used an
annual discount rate of 3% as recommended in the report-
ing standards for cost-effectiveness analyses.22
The base-case analysis was performed for men age 70
years in average health. We chose men for the base-case
analysis because the prevalence of AAA is five-fold greater
in men than women. In addition, our previous model
showed little difference in outcome between men and
women.5 We also analyzed the outcome for men in poor
health by doubling the operative risk and reducing the life
expectancy to equal to a man in average health but 8 years
older. Sensitivity analysis was used to evaluate the stability
of the conclusion and to determine which factors most
influenced the results when varied across their plausible
range.
RESULTS
Base-case analysis
For 70-year-old men in average health, ENDO yielded
an average QALE of 7.09 years and OPEN yielded 7.03
Table I. Probabilities used in model
Parameter Base case
Range tested in
sensitivity analysis Reference
ENDO
Mortality rate*
Overall 0.02 0-0.10 EUROSTAR
Age 60 to 64 y 0.01 0-0.10 EUROSTAR
Age 65 to 69 y 0.01 0-0.10 EUROSTAR
Age 70 to 74 y 0.02 0-0.10 EUROSTAR
Age 75 to 79 y 0.03 0-0.10 EUROSTAR
Age 80 y 0.05 0-0.10 EUROSTAR
Permanent morbidity rate† 0.01 ‡ 2, 18, 19
Early conversion 0.015 0-0.05 EUROSTAR
Mortality rate† 0.10 ‡ EUROSTAR
Permanent morbidity rate† 0.05 ‡
Late conversion (annual rate) 0.01 0-0.05 EUROSTAR
Mortality rate† 0.17 ‡ EUROSTAR
Permanent morbidity rate† 0.05 ‡
ENDO revision (annual rate) 0.09 0-0.20 EUROSTAR
Mortality rate† 0.01 ‡ EUROSTAR
Permanent morbidity rate† 0.005 ‡
Rupture rate after ENDO (annual rate) 0.0046 0-0.02 EUROSTAR
Mortality rate after rupture after ENDO 0.56 0.2-0.9 EUROSTAR
OPEN
Mortality rate*
Overall 0.052 0-0.15 5
Age 60 to 64 y 0.017 0-0.15 5
Age 65 to 69 y 0.03 0-0.15 5
Age 70 to 74 y 0.04 0-0.15 5
Age 75 to 79 y 0.062 0-0.15 5
Age 80 to 99 y 0.102 0-0.15 5
Permanent morbidity rate† 0.015 0-0.15 16
Revision (annual rate) 0.01 0-0.02 17
Mortality rate† 0.25 ‡ 17
Permanent morbidity rate† 0.05 ‡
Other values
Excess annual mortality rate associated with AAA disease 0.03 0-0.05 15, 20, 21
Excess mortality associated with permanent morbidity 0.15 ‡ 22, 23
Quality of life adjustment for permanent morbidity 0.65 0.3-1.0 24
Quality of life adjustment for undergoing repair (QALYs deducted) 25
ENDO 0.02 0.1-0.4
OPEN 0.08 0.04-0.16
Annual discount rate 0.03 0.0-0.3 25
*Mortality risks shown were assigned to midpoint of age ranges, and intermediate values then were determined with linear interpolation. OPEN operative
mortality rate for age 60 years was determined with “best fit” of logarrithmic function applied to these data.
†For average 70-year-old man (probability of event adjusted for age with odds ratio of 1.5 per decade of life).
‡Odds of these events were varied in sensitivity analysis by factor of 2.
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years. This represents a difference of only 0.06 QALYs or
approximately 3 weeks. For 70-year-old men in poor
health, ENDO provided 4.98 QALYs and OPEN provided
4.82 QALYs, a difference of 2 months.
Sensitivity analysis
Age. The effect of age on QALE for men in average
health undergoing AAA repair is shown in Fig 1. Cohorts of
younger patients can expect longer QALE with OPEN, and
older patients do better with ENDO. The threshold age at
which the two strategies are equivalent is 64 years. It is
important to note that the difference between the two
strategies is small across the entire age range as shown in Fig
1 (3 quality-adjusted months at age 85 years).
For men in poor health, ENDO yields longer QALE
across the entire age range tested as seen in Fig 2. However,
the difference is again relatively small (3 quality-adjusted
months at age 85 years).
Operative mortality. Varying OPEN operative mor-
tality in the decision model influenced the optimal strategy
such that for 70-year-old men an OPEN operative mortal-
ity rate of less than 3% would favor OPEN (Table II).
However, the differences between the two strategies was
small across most of the range tested (3 months differ-
ence in QALE until operative mortality rate was6%). The
difference in QALE was more than 6 months when opera-
tive mortality rate exceeded 10%. Similarly, if the ENDO
operative mortality rate exceeded 2% for 70-year-old men,
OPEN would be favored but again by a small margin (3
months until ENDO operative mortality rate was 6%).
Varying operative mortality rate in 60-year-old and 80-
year-old-men across plausible ranges affected the optimal
strategy but again only by small amounts (Table II).
Sensitivity analysis of ENDO and OPEN operative
mortality for 70-year-old men of average health shows that
for most likely scenarios, ENDO will be preferred but by a
small margin (Fig 3). For 60-year-old men in average
health, there is little benefit of one therapy over the other
for most patients. For 80-year-old men in average health,
ENDO is likely to confer the greatest benefit in almost all
situations. In all age groups, as OPEN operative mortality
rate increases, the survival advantage of ENDO increases. It
is only the unlikely scenario in which patients would have a
low operative mortality rate with OPEN but a high opera-
tive mortality rate with ENDO that OPEN would be clearly
preferred.
Rupture risk after ENDO. ENDO is the preferred
strategy for 70-year-old men until the annual rupture rate
exceeds 0.7%. The difference in QALE is less than 3 months
until this rate exceeds 1.7% per year. For 60-year-old men,
OPEN is preferred unless the annual rupture rate is less
than 0.4%. The difference in QALE was less than 3 months,
however, until the rupture rate exceeded 1.2% per year. For
80-year-old men, ENDO was preferred until the rupture
rate exceeded 2.0% per year. However, an annual rupture
rate from 0 to 2% did not yield a survival advantage of more
than 3 months for either strategy in the oldest age group
(Table II).
Because of the developing nature of endovascular sur-
gery, the level of certainty is lower for ENDO outcomes
than for OPEN. Fig 4 shows the combined effect of two key
variables: ENDO operative mortality and annual rupture
risk after ENDO. As the rupture risk increases, ENDO
operative mortality rate must decrease for ENDO to remain
the preferred strategy. In addition, if both rupture risk and
operative risk with ENDO increase only slightly, ENDO
may no longer be the preferred strategy.
Late conversion to OPEN. For 70-year-old men,
ENDO was preferred until the annual rate of late conver-
sion was more than 1.7%. However, the difference in
QALE was less than 3 months across the entire range of
values tested. For 60-year-old men, OPEN was preferred
until the late conversion rate was less than 0.7% per year.
When this value was more than 3%/y, the QALE advantage
of OPEN was more than 3 months. For 80-year-old men,
ENDO was preferred until the late conversion rate was
more than 5.0% per year, but the difference in QALE was
less than 3 months across the entire range tested (Table II).
Fig 1. Effect of age on QALE for men in average health.
Fig 2. Effect of age on QALE for men in poor health.
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Revision after ENDO and OPEN reoperation.
Varying the rate of ENDO revision or OPEN reoperation
affected the results but in all cases by less than 3 months for
60-year-old and 70-year-old men (Table II). For 80-year-
old men, varying these parameters across their plausible
range did not change the optimal strategy, which was
ENDO.
Other parameters. If the mortality rate of reoperation
after OPEN repair was below 13%, OPEN became favored.
However, the survival difference was less than 3 months for
either ENDO or OPEN across the entire range of values
tested for this variable. Similarly, if the risk of permanent
major morbidity after ENDO was above 2.3%, OPEN
became favored, but again neither strategy provided more
than 1 month increase in QALE across the entire range of
values. Increasing the disutility of OPEN from 4 weeks to 8
weeks increased the benefit of ENDO, but the difference
was still less than 2 months of QALE. Varying the annual
discount rate from 0 to 30% did not change the optimal
strategy for 70-year-old men.
Patients in poor health. For patients in poor health,
sensitivity analyses were similar. For 70-year-old and 80-
year-old men, varying most parameters affected the out-
come but with less than 3 months survival advantage for
either strategy across the entire range of values tested. For
60-year-old men, there was a more substantial survival
advantage (6 months) for ENDO but only at extremes of
the range of variables tested (open operative mortality rate,
9%; endovascular operative mortality rate, 8%).
DISCUSSION
Our model shows little difference in QALE between
ENDO and OPEN AAA repair. Our base case analysis
showed a small advantage for ENDO over OPEN. How-
ever, in sensitivity analysis, this small advantage was not
persistent. Varying each of the important variables across
plausible ranges showed only small survival advantages for
either strategy. Therefore, we cannot identify a superior
strategy with decision analysis and the best data currently
available.
Patel et al6 found a 0.42 QALY advantage of ENDO
over OPEN for 70-year-old subjects. However, this report
was on the basis of preliminary data from early US trials
performed at a small number of carefully selected centers.
Rupture after ENDO had not yet been reported. This
model uses broad-based, multicenter data for both OPEN
and ENDO strategies. This model also uses age-stratified
operative mortality for both groups.
A recently presented abstract with decision analysis to
compare ENDO with OPEN also found a slight benefit
with ENDO over OPEN of 0.22 QALYs.23 This is consis-
tent with our results and also suggests that the difference
between the two strategies is small. These authors also
noted that the result was sensitive to rupture risk and
reintervention (conversion to open or endovascular revi-
sion) in the ENDO group. In our model, the benefits of
ENDO were also dependent on a low rate of rupture and
reintervention after ENDO. However, we also found the
results to be sensitive to changes in ENDO and OPEN
operative mortality.
Several limitations exist in this study. First, although
the results with OPEN have not changed substantially over
time,14 ENDO is a new technique that continues to evolve.
It is possible that endograft technology will continue to
improve with development of more durable devices with
better fixation, which can be placed with decreased imme-
diate and long-term complication rates. Therefore, results
with ENDO may improve over time. However, it is also
possible that longer follow-up will reveal an increase in
adverse events. Thus, our conclusions apply only to current
EUROSTAR results.
Second, we used average outcomes from broad-based,
multicenter databases. Our model does not take into ac-
count differences in outcomes between centers. It is possi-
ble that some centers may have results that are superior or
inferior to those used in the model from EUROSTAR or
Medicare claims data. Therefore, each center must adjust
the overall conclusion in accordance with their own results.
However, one must also consider that in individual centers
of excellence the results with OPEN are often better than
Table II. Results of sensitivity analysis
Variable Base case Range
Threshold at which ENDO is favored
Age 60 y Age 70 y Age 80 y
OPEN operative
mortality rate
Age 60: 1.7% 0-15% 2% 3% 4%
Age 70: 3.5%
Age 80 : 10%
ENDO operative
mortality rate
Age 60 : 1% 0-10% None 2% 7%
Age 70 : 1.5%
Age 80 : 5%
Rupture rate after
ENDO (%/y)
0.46% 0-2% 0.4% 0.7% 2%
Late conversion to
OPEN (%/y)
1% 0-5% 0.7% 1.7% 5%
ENDO revision
rate (%/y)
9% 0-20% 0.5% 17% All
OPEN reoperation
rate (%/y)
1% 0-2% 1.2% 0.5% All
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Fig 3. Effect of OPEN and ENDO operative mortality in determining the amount of extra QALE gained by choosing
one strategy over the other for men in average health. In the lightly shaded region of graph, the difference in QALE
between the two strategies is less than 3 months. In the darkest region, this difference exceeds 6 months.
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those from population-based reports as well. It is likely that
individual centers with lower complication rates after
ENDO will also have lower operative mortality rates after
OPEN. This effect would minimize any difference between
the two strategies. It also underscores the need for individ-
ual centers performing ENDO to monitor their results to
determine which therapy is optimal in their hands. If there
is to be any benefit with ENDO over OPEN, it is depen-
dent on a low perioperative and long-term complication
rate.
Third, our use of lower operative mortality for ENDO
relative to OPEN for all ages may be considered a limita-
tion. Some investigators have suggested that there is no
difference in operative mortality between the two strategies
because no published trial comparing OPEN with ENDO
has shown a significant difference between the two. How-
ever, our use of multicenter and population-based age-
stratified mortality rates from EUROSTAR and the Medi-
care database seems justified because these are currently the
most reliable broad-based data available. In addition, a
recently presented metaanalysis did show a significant re-
duction in operative mortality with ENDO compared with
OPEN.24 We must also remember that the EUROSTAR
registry includes patients who were considered unfit for
OPEN. It is likely that the patients in the EUROSTAR
registry and those in the Medicare database are not equiv-
alent. Therefore, it is more likely that we have biased our
model somewhat against ENDO.
Fourth, we did not evaluate costs in this study. It is
possible that a large cost differential may have an influence
on decision making when choosing ENDO versus OPEN.
However, because the small benefit of ENDO was sensitive
to many variables, it is likely that no firm conclusions can be
made regarding the cost effectiveness of ENDO versus
OPEN.
Finally, although our model suggests that the oldest
patients in poor health might benefit more from ENDO
than from OPEN, we did not consider the option of
observation in these patients with limited life expectancy.
Finlayson et al5 showed that these patients derived minimal
benefit from ENDO over observation.
Medical procedures that offer only a small increase in
QALE are sometimes considered appropriate, particularly
when there is only a small (or no) additional cost associated
with the life-prolonging procedure. Table III shows the
additional QALE associated with coronary artery bypass,
AAA repair, and carotid endarterectomy.5,25-27 Although
the additional life expectancy benefit with carotid endarter-
ectomy compared with medical management was small, the
benefit persisted under most scenarios tested in sensitivity
analysis. In contrast, in this study, the small benefit of
ENDO did not persist as each of multiple important vari-
ables was varied across its plausible range. Therefore, it is
unlikely that one procedure would be consistently prefera-
ble to the other.
The primary difference between the two strategies,
ENDO versus OPEN, is the timing of the risk of death and
adverse events. Operative mortality rate with ENDO was
half that of OPEN (or less) for all ages. However, patients
who undergo ENDO face ongoing risks of rupture and late
conversion, both of which have significant mortality rates.
Although the risks after surviving OPEN repair are not
Fig 4. Combined effect of ENDO operative mortality rate and rupture risk after ENDO.
Table III. QALE gains with common surgical
procedures for men of specified ages
Intervention Benefit (QALYs)
CABG, 1-vessel disease* 0.5
CABG, 2-vessel disease* 1.1
CABG, 3-vessel disease* 3.2
CABG, left main disease* 6.2
CEA, asymptomatic† 0.25
CEA, symptomatic‡ 0.35
Elective AAA repair (5 cm)§ 4.1
*55-year-old men versus medical therapy.
†67-year-old men.
‡65-year-old men.
§70-year-old men versus no repair.
CABG, Coronary artery bypass grafting; CEA, carotid endarterectomy.
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zero, they are substantially lower than those after ENDO
repair. Given that there is minimal difference between the
two strategies, it would seem appropriate that patient pref-
erences should be a strong determinant when choosing
between them. Some patients will prefer to have a slightly
higher initial operative risk knowing that they will be better
protected in the long term. Others will prefer to defer the
upfront risk, particularly those who are older or in poor
health, in whom the difference between the initial operative
mortality in the two strategies is larger. For example, the
difference in operative mortality rate between OPEN and
ENDO in our model was 5% for 80-year-old men but less
than 1% for those 60 to 64 years. In addition, when told
that overall outcome is similar, some patients will prefer
ENDO to avoid the relatively prolonged postoperative
disability after OPEN. The inconvenience of follow-up
after ENDO may cause some to prefer OPEN, particularly
those who are younger and healthier, who have only a
slightly increased operative risk with OPEN relative to
ENDO. Patients who must travel great distances or with
limited access to transportation may also prefer OPEN to
reduce surveillance requirements.
Our study suggests that randomized trials comparing
ENDO with OPEN would be appropriate, given the nearly
identical outcomes of these competing strategies with cur-
rently available data. Such trials are currently underway in
Europe (EVAR I and DREAM). A second arm of the
EVAR trial (EVAR II) will randomize patients considered
unfit for OPEN to ENDO versus observation. These trials
will add data to improve our decision making for choosing
the best therapeutic intervention for patients with AAA.
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DISCUSSION
Dr K. Craig Kent (New York, NY). Marc, that was a great
analysis, and I think most of the conclusions that you have made
are fairly logical.
Of course, we had all hoped and anticipated that our new
minimally invasive treatment for aneurysms would prolong the life
of our patients. Dr Schermerhorn has told us today that it does but
this increase can be measured in days and months rather than years.
I did my back-of-the-envelope calculation. Considering that a
70-year-old individual already lives 25,550 days, one could argue
that sticking around for another 30 or so is seemingly irrelevant. I
guess it depends a bit on what you plan to do those final 30 days,
but I tend to agree with their conclusion.
Realize, however, that Dr Schermerhorn’s findings with re-
gard to extension of life are not uncommon in decision analysis
reports. Many of the interventions that we consider commonplace
and well accepted extend life by only a few days or a month. For
example, in an analysis performed by this same group, carotid
endarterectomy for asymptomatic disease, versus watchful waiting,
extended a patient’s life by only 3 months. In another analysis of
the use of CABG, the extension of life provided by this well-
established intervention is only 7 months. It is rare for many of our
currently available medical interventions to add more than a few
months to a patient’s life. Perhaps this is testimony to how futile
our work as physicians really is.
This leads to my first question.
An endovascular repair of aneurysms extends a person’s life 2
to 3 months. Isn’t this procedure by your own analysis as effective
as carotid endarterectomy? Shouldn’t your conclusions regarding
the effectiveness of endografts be more favorable?
All of us who place endografts realize that the popularity of
this technique with patients is related not to patients believing that
they are going to live longer following the procedure but to their
desire to have a less invasive, less morbid surgery that allows a faster
recovery. They are interested in the present not necessarily the
future. Is there any way to include this factor in your analysis? Are
patients willing to take in trade a few months at the end of life for
a better quality of life in the perioperative period?
You have already attempted to compensate for this by applying
a disutility or subtracting 4 weeks of life from a patient who
undergoes an aneurysm repair. Isn’t this period too short? Open
AAA repair patients are usually not completely back to a normal
state of health for at least 2 months and sometimes longer. What
happens if you extend this disutility for 2 months or 3 months? Will
this not make endovascular repair much more appealing?
I commend you and your group for this provocative study. We
need to be thoughtful about our procedures and their benefit to
society. Marc, you are asking the right questions.
Dr Marc L. Schermerhorn. Thank you, Dr Kent, for your
kind comments and questions.
When we first undertook this project, we wanted to ask ourselves
the same question that has been asked by several other people in some
journals, basically should we be doing this procedure anymore given
the ongoing risk of rupture and need for these late reinterventions,
which all seem to be more common than we had initially hoped. And
so we approached it from that perspective. I think our answer now is
yes, we should be continuing this experiment.
In terms of the extra life expectancy, I agree that even small
gains in life expectancy can be important from a societal perspec-
tive, which is how we should view these decision analyses, rather
than just on an individual patient basis. However, at least with our
current model, the end result was sensitive to so many different
variables that we cannot be certain about that result. It would take
multiple variables all being improved to show a dramatic difference
between open and endovascular repair. Whereas when we varied
one or two factors, there was very little difference across the whole
range. So, based on that, we thought that we really could not
define a better procedure.
In terms of the disutility associated with the open repair, we did
choose 4 weeks of life. I agree that it normally takes 2 or 3 months for
people to fully recover after an open aneurysm repair, but their quality
of life is not zero during that time, so we thought that 4 weeks was a
good compromise. However, we did check this with sensitivity anal-
ysis, and yes, for each month that you subtract, that will add almost
another month to the difference in the life expectancy. So, it will
definitely make endovascular repair more favorable, but I think in the
long run our conclusion would still stand.
Dr Bruce J. Brener (Millburn, NJ). I am interested in the
management of the high-risk patient. Would you comment on
your analysis of the issue of endovascular repair versus no surgery in
the high-risk patient?
Dr Schermerhorn. although not covered in this report, we
have previously analyzed the question of whether either open or
endovascular repair is valuable in hish-risk patients. In that paper,
Sam Finlayson showed that endovascular repair should not change
the threshold at which we operate compared with open surgery.
He found that the appropriate diameter threshold increases for
older, very sick patients, and he found that there was little benefit
of either open or endovascular repair in those patients.
Dr John J. Ricotta (Stony Brook, NY). Why did you use a
70-year-old healthy person as your base case? And what would
happen if you used an older person that we all, at least viscerally,
feel would benefit more from an endovascular approach, some-
body over 75 or somebody 80.
I could not figure out whether you had already dissected that
out, and I did not understand the answer. But it would seem to me
that the real issue is, if it is going to be beneficial, it is going to be
most beneficial in these older people or people with a comorbidity.
Dr Schermerhorn. I agree with everything that you said. We
did not use healthy patients. We took 70-year-olds in average
health with abdominal aortic aneurysms. These patients have a
reduced life expectancy relative to similar patients without AAA.
We also modeled poor health by decreasing life expectancy
and increasing operative risk. And in the patients in poor health,
there was more benefit for endovascular repair relative to those in
average health. Also, the benefit with endovascular repair increased
with older age, both for the average health group and for the group
in poor health, with a wider difference for those in poor health. So,
our analysis lends some support to our natural tendency to want to
offer endovascular repair to older patients in poor health.
Dr Brener. Would you comment on the issue of bias. You
were looking at the EUROSTAR data and you were looking at a
process, which is changing over time. Devices are getting better;
surgeons are more experienced. Some patients are probably in
trials, therefore good-risk patients. Others are poor risk. How do
you answer the questions about bias?
Dr Schermerhorn. I think there is definitely some bias intro-
duced by using the EUROSTAR database. It included a number of
patients who were considered unfit for open repair, and they also
had some patients who were even considered unfit for general
anesthesia. So, I think we have biased a little bit against endovas-
cular repair with our analysis and perhaps we can factor that out
when we get more breakdown of the data.
But I should mention that in the sensitivity analysis, even if
you decrease the endovascular operative mortality to zero, it is still
not a very large benefit. So, I think that the overall conclusion
would still stand.
In terms of the long-term durability, that is an important point
also. It is an evolving technique, and we do not know how these
results are going to stand up 5 years from now. The grafts may be
better and they may be easier to deploy, so that we can do that with
fewer complications and a lower conversion rate. However, we may
also find that they are just not durable after 5 or 10 years, so our
analysis is limited to our current understanding.
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